Alcohol use disorder (AUD) is a brain disorder affecting more than 28 million adults in the United States, according to the AUD is characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences
HSAs offer a significant advantage: unused balances roll over year to year and earn investment growth, making them ideal for ongoing weight loss therapy that extends beyond a single calendar year
The research peptide supply chain is largely unregulated
The combined effect is greater than either lever alone, which is why 15 mg of tirzepatide produces weight loss that 2.4 mg of semaglutide cannot match
GLP-1 receptor agonists and related incretin-based peptides reduce HbA1c, body weight and certain cardiovascular risk markers in appropriate patients, especially when combined with nutrition and activity interventions
Deficiency in vitamin B12 can result in symptoms such as fatigue, weakness, tingling sensations, and difficulty concentrating
